Covered recipient · General Payments record
MAKAYLA I BABISH
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$1,270.34
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $308.21 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $143.01 | 8 |
| Novo Nordisk AS | $63.95 | 4 |
| Lilly USA, LLC | $31.04 | 2 |
| Janssen Pharmaceuticals, Inc | $23.71 | 1 |
| Astellas Pharma US Inc | $17.84 | 1 |
| INTRA-SANA LABORATORIES | $15.40 | 1 |
| ABBVIE INC. | $13.26 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.26 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106466026 | CMS |
| Amgen Inc. | $25.00 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498924 | CMS |
| Amgen Inc. | $23.79 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498926 | CMS |
| Amgen Inc. | $9.04 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498928 | CMS |
| Amgen Inc. | $27.14 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498930 | CMS |
| Amgen Inc. | $11.67 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498932 | CMS |
| Amgen Inc. | $19.90 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498934 | CMS |
| Amgen Inc. | $10.06 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117498936 | CMS |
| Amgen Inc. | $16.41 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117194712 | CMS |
| Astellas Pharma US Inc | $17.84 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139515553 | CMS |
| Intra-Sana Laboratories | $15.40 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138620994 | CMS |
| Janssen Pharmaceuticals, Inc | $23.71 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077913933 | CMS |
| Lilly USA, LLC | $15.12 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135742488 | CMS |
| Lilly USA, LLC | $15.92 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135807887 | CMS |
| Novo Nordisk Inc | $13.66 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100485389 | CMS |
| Novo Nordisk Inc | $17.43 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100394162 | CMS |
| Novo Nordisk Inc | $13.95 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100348686 | CMS |
| Novo Nordisk Inc | $18.91 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100393000 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.